Magyar onkologia最新文献_第3页

[Could the administration of immune checkpoint inhibitors be discontinued after 2 years of application? Pros and cons for the development of a national guideline.] 免疫检查点抑制剂可以在使用2年后停用吗？制定国家指导方针的利弊

Magyar onkologia Pub Date : 2026-03-12 Epub Date: 2026-02-20

László Mangel, Tímea Balatoni, Krisztina Bogos, Rolland Gyulai, Anikó Maráz, Gábor Rubovszky, Gyula Ostoros, Lilla Tamási, Csaba Polgár

{"title":"[Could the administration of immune checkpoint inhibitors be discontinued after 2 years of application? Pros and cons for the development of a national guideline.]","authors":"László Mangel, Tímea Balatoni, Krisztina Bogos, Rolland Gyulai, Anikó Maráz, Gábor Rubovszky, Gyula Ostoros, Lilla Tamási, Csaba Polgár","doi":"","DOIUrl":"","url":null,"abstract":"Despite their undeniable effectiveness, the spectacular increase in the number of antitumor immunotherapies (IT) in recent years has resulted in a substantial organizational and financial challenge on healthcare systems, and prolonged treatments can be burdensome for patients as well. There is an ongoing debate about how long it is optimal to continue palliative IT, or it can be discontinued after 2 years without an increased risk of relapse. Conclusively, it could be especially justified in complete tumor remission, however stable disease does not preclude it, and the decision may be strengthened by chronic complications, comorbidity state, patient preference, and PET/CT negativity, double IT, and lack of prior oligo- progression. Nevertheless, all this requires individual consideration, tumor-board discussion, and it is recommended to gradually prepare patients psychologically. In summary, while maintaining the possibility of reinduction, the discontinuation of palliative IT should always be considered after 2 years application (even after 1 year in melanoma), aiming for the longest treatment-free survival of our patients and minimizing the feeling of having a chronic and incurable disease.","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"70 1","pages":"41-50"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12990076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Daily online adaptive irradiation of bladder tumors with individualized safety margin creation]. 【每日在线自适应照射膀胱肿瘤及个体化安全裕度创建】。

Magyar onkologia Pub Date : 2026-03-12 Epub Date: 2025-03-03

Gabriella Dóra Pulugor, Ádám Gáldi, Levente Varga, Kliton Jorgo, László Gesztesi, András Herein, Domonkos Szegedi, Zsuzsa S Kocsis, Tibor Major, Csaba Polgár, Zoltán Takácsi-Nagy, Péter Ágoston

{"title":"[Daily online adaptive irradiation of bladder tumors with individualized safety margin creation].","authors":"Gabriella Dóra Pulugor, Ádám Gáldi, Levente Varga, Kliton Jorgo, László Gesztesi, András Herein, Domonkos Szegedi, Zsuzsa S Kocsis, Tibor Major, Csaba Polgár, Zoltán Takácsi-Nagy, Péter Ágoston","doi":"","DOIUrl":"","url":null,"abstract":"Aim: Daily online adaptive radiation therapy (OART) allows the creation of individualized safety margins based on daily optimized treatment planning, taking into account daily anatomy variations. The goal of our work was to compare the protocols and safety margins of a non-adapted, image- guided radiation therapy (IGRT), a published Danish and the National Institute of Oncology of Hungary (NIO) protocol in the first eight bladder cancer patients treated with OART.Methods: Three cone beam CTs (CBCT) were taken during the first three fractions: after patient positioning, after adaptation, and at the end of treatment. Bladder contours, extensions and margins were established on all CT images (n=512). Intraadaptational, intrafractional and interfractional changes were examined.Results: Regarding PTV, a mean reduction of 12.2% could be achieved using the Danish, and 34.1% using the NIO protocol compared to IGRT. Healthy tissue irradiated by the prescribed dose could be reduced. The target volume miss is decreased as well.Conclusions: PTV could be reduced and optimized, increasing healthy tissue protection using OART.","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"70 1","pages":"23-31"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12990079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Dosimetric comparison of model-based and conventional calculation algorithms in high-dose-rate brachytherapy of head and neck tumours]. [高剂量率头颈部肿瘤近距离放疗中基于模型和传统计算算法的剂量学比较]。

Magyar onkologia Pub Date : 2026-03-12 Epub Date: 2026-01-24

István Bodács, Zoltán Takácsi-Nagy, Tibor Major

{"title":"[Dosimetric comparison of model-based and conventional calculation algorithms in high-dose-rate brachytherapy of head and neck tumours].","authors":"István Bodács, Zoltán Takácsi-Nagy, Tibor Major","doi":"","DOIUrl":"","url":null,"abstract":"Aim: To investigate the effect of a model-based calculation algorithm that takes into account tissue inhomogeneities and real scattering conditions, on dose-volume parameters in brachytherapy for head and neck tumours.Methods: We recalculated the treatment plans of twentyfour patients treated with brachytherapy using the modelbased Advanced Collapsed Cone Engine (ACE) algorithm. High-dose volumes in the target and volumes irradiated with lower doses were determined. We calculated the doses to the organs at risk for the small volumes receiving high doses and the average doses.Results: The conventional calculation algorithm calculated higher doses than ACE for almost all parameters. The difference was less than 1% for V100 and D90. Among the volumes enclosed by the isodose surfaces, the difference was greater between the high-dose volumes and the low-dose volumes. The doses to the mandible were 2-3% lower with ACE, while the doses to the skin were 4-7% lower. The difference to the salivary glands was between 5-8%, while the doses to the spinal cord were the same.Conclusions: When treating head and neck tumours, the traditional calculation algorithm overestimates the doses to the target volume and organs at risk. The introduction of the new calculation algorithm into clinical practice is not yet recommended.","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"70 1","pages":"33-39"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12990080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Comorbidities affecting abiraterone treatment in patients with metastatic castration-resistant prostate cancer: a meta- analysis]. [影响转移性去势抵抗性前列腺癌患者阿比特龙治疗的合并症：荟萃分析]。

Magyar onkologia Pub Date : 2026-03-12 Epub Date: 2025-03-13

Barna Budai, Bertalan Fekete, Krisztina Biró, Enikő Lénárt, Attila Patócs, Lajos Géczi

{"title":"[Comorbidities affecting abiraterone treatment in patients with metastatic castration-resistant prostate cancer: a meta- analysis].","authors":"Barna Budai, Bertalan Fekete, Krisztina Biró, Enikő Lénárt, Attila Patócs, Lajos Géczi","doi":"","DOIUrl":"","url":null,"abstract":"Aim: Optimizing the treatment of metastatic prostate cancer is important for reducing mortality. Therefore, it is essential, among others, to know the predictive markers of abiraterone acetate (AA) treatment in metastatic castration-resistant prostate cancer (mCRPC). We aimed to clarify the predictive factors of AA treatment of mCRPC patients, and particularly the predictive role of comorbidities and co-medication based on meta-analysis of published data.Methods: Meta-analysis of the results of multivariate analysis found in 120 publications examining at least 100 cases.Results: Besides clear predictors of progression-free and overall survival, opioid use, pain, cerebrovascular diseases, dyslipidemia, statin treatment, bisphosphonate/antiresorptive treatment and metabolic syndrome significantly affect the risk of progression and survival.Conclusions: Since the analysis of comorbidities is based on relatively few observations, further studies are needed to clarify the predictive impact of comorbidities and co-medication in order to improve the effectiveness of treatment in mCRPC in an individualized manner.","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"70 1","pages":"53-68"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12990081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Very accelerated partial breast irradiation (VAPBI) with high-dose-rate interstitial brachytherapy following breast- conserving surgery of low-risk breast cancer patients]. 低危乳腺癌患者保乳手术后高剂量间质近距离极加速部分乳房照射（VAPBI）。

Magyar onkologia Pub Date : 2026-03-12 Epub Date: 2025-03-03

Norbert Mészáros, Viktor Smanykó, Tibor Major, Georgina Fröhlich, Zoltán Takácsi-Nagy, Csaba Polgár

{"title":"[Very accelerated partial breast irradiation (VAPBI) with high-dose-rate interstitial brachytherapy following breast- conserving surgery of low-risk breast cancer patients].","authors":"Norbert Mészáros, Viktor Smanykó, Tibor Major, Georgina Fröhlich, Zoltán Takácsi-Nagy, Csaba Polgár","doi":"","DOIUrl":"","url":null,"abstract":"Aim: To evaluate the efficacy and safety of high-dose-rate interstitial VAPBI in women undergoing conservative surgery for low-risk, early invasive breast cancer.Methods: Between December 2018 and December 2024, 28 patients were enrolled in this prospective, non-randomized trial. Targeted radiotherapy of the tumor bed was delivered using thin plastic catheters placed at the surgical site, through which a high-dose-rate Ir-192 source was administered. Prescribed doses were 4×6.25 Gy (25 Gy total) or 3×7.45 Gy (22.35 Gy total), delivered over two consecutive working days.Results: With a median follow-up of 60 months (range: 9-84), local recurrence was observed in 2 patients (7.1%). One patient (3.6%) died of liver metastases, and another (3.6%) from a second primary tumor. The 5-year local control rate was 93.7% (95% CI: 88.1-99.4). Late toxicity was limited to grade 1 fibrosis in 6 patients (21.4%) and grade 1 pain in 2 patients (7.1%); no grade ≥2 toxicities occurred. Cosmetic results were excellent or good in all cases.Conclusions: Reducing interstitial treatment duration from 5 to 2 days appears safe and more convenient for patients.","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"70 1","pages":"15-20"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12990077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prediction of immune checkpoint inhibitor therapy in urothelial carcinoma: integrated analysis of molecular patterns and clinical factors 预测免疫检查点抑制剂治疗尿路上皮癌：分子模式和临床因素的综合分析

Magyar onkologia Pub Date : 2026-03-12 Epub Date: 2026-01-10

Melinda Hermann-Váradi

{"title":"Prediction of immune checkpoint inhibitor therapy in urothelial carcinoma: integrated analysis of molecular patterns and clinical factors","authors":"Melinda Hermann-Váradi","doi":"","DOIUrl":"","url":null,"abstract":"Aim: To identify clinicopathological and molecular factors influencing immune checkpoint inhibitor efficacy in urothelial carcinoma (UC).Methods: We analyzed >200 patients with locally advanced or metastatic UC treated with pembrolizumab or atezolizumab. Gene expression profiling was performed on 100 tumors, and baseline and on-treatment serum soluble PD-L1 (sPD-L1) levels were measured. Integrated clinicopathological- molecular survival model was developed.Results: Objective response rate (ORR) and overall survival (OS) were comparable to clinical trials. Poor ECOG status, metastases, low hemoglobin, and Bellmunt risk factors independently predicted shorter OS. Gene expression analysis identified 23 genes associated with OS and additional genes linked to response; PSMB10 showed validated prognostic and predictive value. Neuronal and TCGA-luminal infiltrated subtypes had the best outcomes, and high neuronal signatures correlated with longer OS. Elevated baseline sPD-L1 predicted poor OS.Conclusions: Integrating clinical and molecular biomarkers improves survival stratification and may refine immunotherapy selection in UC.","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"70 1","pages":"85-87"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[History of Hungarian radiotherapy - from radium needles to the CyberKnife]. [匈牙利放射治疗的历史——从镭针到射波刀]。

Magyar onkologia Pub Date : 2026-03-12 Epub Date: 2025-11-23

Csaba Polgár, Géza Varjas, János Fodor

引用次数: 0

[rare subtype of kidney cancer - Pigmented microcystic chromophobe carcinoma]. [罕见肾癌亚型-色素微囊性憎色癌]。

Magyar onkologia Pub Date : 2026-03-12 Epub Date: 2025-07-01

Luca Szalai, Imola Adamik, Judit Betenbuk, Zsuzsa Sándor, Péter Dombóvári, Péter Tenke, Tibor Szarvas, Levente Kuthi

{"title":"[rare subtype of kidney cancer - Pigmented microcystic chromophobe carcinoma].","authors":"Luca Szalai, Imola Adamik, Judit Betenbuk, Zsuzsa Sándor, Péter Dombóvári, Péter Tenke, Tibor Szarvas, Levente Kuthi","doi":"","DOIUrl":"","url":null,"abstract":"Aim: Chromophobe renal cell carcinoma (chRCC) is a morphologically heterogeneous tumor type, with one of its rarest forms being pigmented microcystic chromophobe carcinoma.Methods: In our paper, we present the case of a 68-year-old man, in whom imaging studies identified a 32 mm kidney tumor.Results: The tumor was surgically removed, and pathological analysis revealed a cystic tumor with unusual morphology, composed of eosinophilic cells. Brown pigment and hemorrhage were present in the lumen of the cysts. Immunohistochemically, the tumor showed diffuse CD117, PAX8, and E-cadherin expression, with focal positivity for CK7 and CD10. GATA3, MelanA, HMB45, cathepsin K, CK20, chromogranin A, and synaptophysin reactions were negative. Chromosome 17 monosomy could not be detected using double-labeled HER2/cen17 chromogenic in situ hybridization. The patient recovered well after the operation and is currently under oncological care.Conclusions: To the best of our knowledge, this is the first documented case of pigmented microcystic chromophobe carcinoma diagnosed in Hungary. The aim of this paper is primarily to raise awareness, and in the course of our work, we will review the morphological subtypes of chRCC and the differential diagnostic entities.","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"70 1","pages":"69-73"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12990078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Anna AI - a voluntary AI tool to complement psychosocial care in oncology]. [安娜人工智能-一个自愿的人工智能工具，以补充肿瘤的社会心理护理]。

Magyar onkologia Pub Date : 2026-03-12 Epub Date: 2025-08-22

Ágnes Riskó, Bence Csernák

引用次数: 0

[Diagnostics and therapy of gastroenterological side effects of immune checkpoint inhibitor therapy]. [免疫检查点抑制剂治疗的胃肠副作用的诊断和治疗]。

Magyar onkologia Pub Date : 2025-12-12 Epub Date: 2025-10-12

Benjámin György Klément, Kamilla Németh, Borbála Székely, Ádám Tarpay

引用次数: 0